H ypertension is an independent, modifiable risk factor for the development of cardiovascular disease (CVD) and the leading cause of disability worldwide.
H ypertension is an independent, modifiable risk factor for the development of cardiovascular disease (CVD) and the leading cause of disability worldwide. 1, 2 Guidelines have traditionally defined hypertension as the current use of an antihypertensive medication or a systolic blood pressure (SBP) ≥140 mm Hg or a diastolic BP (DBP) ≥90 mm Hg, based on at least 2 BP readings obtained on ≥2 occasions. 3, 4 Recently, the American College of Cardiology and American Heart Association (ACC/AHA) BP guidelines recommended changing the BP threshold used to diagnose hypertension to ≥130/80 mm Hg 5 . It is estimated that under these new lower BP thresholds, 31 million US adults with SBP 130 to 139 mm Hg or DBP 80 to 89 mm Hg not on BP medications will be labeled as having hypertension. 6 Of these, the ACC/AHA guidelines recommend starting BP therapy on individuals with a 10-year atherosclerotic cardiovascular disease (ASCVD) risk >10%. It is estimated that 4.2 million US adults would meet this recommendation. 6 These estimates, however, have been based on BP readings taken in 1 occasion; an important consideration because the most BP guidelines recommend establishing a diagnosis of hypertension only after BP is measured on at least 2 occasions. It is critical to properly characterize the individuals who would be newly recommended to start a BP medication because recent research has shown a net benefit from intensive BP therapy only among individuals with a 10-year ASCVD risk >18%. 7 SPRINT (Systolic Blood Pressure Intervention Trial) and the ACCORD-BP trial (Action to Control Cardiovascular Risk in Diabetes-Blood Pressure) are the largest clinical trials evaluating intensive BP targets among individuals with SBP >130 mm Hg at high CVD risk. 8, 9 Even though the newly recommended thresholds for hypertension were largely informed by results from SPRINT, most patients in this trial (and in ACCORD-BP) were on BP medications at baseline. Given that the CVD risk profile of patients on long-standing BP medications may be different than that of patients not on medications despite similar BP values, it is important to determine whether individuals who would be newly recommended to start BP therapy were well represented in these trials and, therefore, establish if there is evidence to support the recommendation for BP treatment initiation in these patients.
We sought to estimate how adopting these newly recommended BP thresholds would impact the prevalence of hypertension among US adults accounting for persistent hypertension (elevated BP on >2 occasions). In addition, we sought to characterize the population that would be newly recommended for initiation of antihypertensive medications and compare them to the demographic and clinical characteristics of participants enrolled in SPRINT and ACCORD-BP trials.
Methods

Data Source
Individual-level data from SPRINT and ACCORD-BP were obtained from the National Heart, Lung, and Blood Institute biological specimen and data repositories information coordinating center (BioLINCC). To request access to the BioLINCC data repository, a completed application form and research proposal should be submitted to National Heart, Lung, and Blood Institute. Data can be accessed through the BioLINCC web site at https://biolincc.nhlbi.nih.gov/home/. National Health and Nutrition Examination Survey (NHANES) data can be accessed through the Centers for Disease Control and Prevention National Center for Health Statistics website at https://www.cdc.gov/nchs/nhanes/ index.htm. The present study was deemed exempt from review by the Institutional Review Board at the University of Washington.
Study Populations
The NHANES 10 is a program of studies conducted by the National Center for Health Statistics to evaluate the health of noninstitutionalized adults and children in the United States. The NHANES sample is selected through a complex multistage design with oversampling for people of black race, Hispanic ethnicity, or both.
The current study includes 5380 participants of the 2013 to 2014 NHANES who were 20 years of age or older, who underwent a health examination at an NHANES mobile examination center with available data for prescription medication use and at least 2 BP readings.
SPRINT enrolled 9361 adults 50 years of age or older with an SBP of at least 130 mm Hg and an increased CVD risk. 8 High CVD risk was defined as history of clinical or subclinical CVD, chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 20 to >60 mL/ min per 1.73 m 2 , a 10-year CVD risk on the basis of the Framingham risk score of ≥15%, or an age of 75 years or older. Patients with diabetes mellitus or prior stroke were excluded. ACCORD-BP enrolled 4733 participants 40 years of age or older with type 2 diabetes mellitus and a glycohemoglobin level of ≥7.5%, an SBP of 130 to 180 mm Hg, and history of CVD. 9 Participants with a body mass index of ≥45 kg/m 2 , a serum creatinine of >1.5 mg/dL, and other serious illnesses were excluded.
BP Measurement
In NHANES, BP was measured by a physician certified in BP measurement using the standardized protocol of the AHA during a single mobile examination center visit. 11, 12 The first BP measurement was recorded after a 5-minute period of rest with 2 additional readings obtained 30 seconds apart using the same arm. A fourth reading was recorded in case ≥1 of the readings were unobtainable.
SPRINT and ACCORD-BP used automated devices to measure BP and used similar classes and numbers of antihypertensive agents. Although SPRINT measured BP in the absence of an observer for the majority of participants (as opposed to ACCORD-BP), similar results for the effect of the intensive BP intervention have been found when analyses have been performed separately in observed or unobserved participants. 13 
Hypertension Definition in NHANES
Prevalent hypertension was defined as current use of an antihypertensive medication or mean SBP or DBP higher than the diagnostic threshold, accounting for the probability of having elevated BP on 2 occasions (persistent hypertension). We used 2 different BP thresholds to diagnose hypertension: the traditional threshold of ≥140/90 mm Hg and the newly recommended threshold of ≥130/80 mm Hg.
Prevalent hypertension estimates incorporate the probability of having persistent hypertension because most guidelines recommend diagnosing hypertension only if elevated BP is present on at least 2 separate days. [3] [4] [5] We considered any participant treated with an antihypertensive medication to have persistent hypertension. For participants not treated with an antihypertensive medication but with mean BP above diagnostic threshold, we incorporated into our statistical analyses the estimated probability that mean SBP or DBP would be elevated when next measured, following an approach we used previously to estimate the prevalence of persistent chronic kidney disease. 14 We based our estimates that BP would be persistently elevated on data collected during NHANES III (1988) (1989) (1990) (1991) (1992) (1993) (1994) , during which 1853 participants underwent repeat BP measurements 2 weeks apart (in the online-only Data Supplement).
Cardiovascular Disease End Points in SPRINT and ACCORD-BP
SPRINT and ACCORD-BP evaluated effect of intensive compared with standard BP treatment targets (<120 versus <140 mm Hg SBP) on a primary composite CVD end point of nonfatal myocardial infarction or stroke or death from cardiovascular causes. SPRINT also included unstable angina and acute heart failure as part of its composite end point. 8, 9 We conducted separate analyses with the original primary prespecified composite CVD end point for each trial.
Other Clinical Characteristics
In NHANES, we defined diabetes mellitus as use of a glucoselowering medication or hemoglobin A1C% ≥6.5%
14 and prevalent CVD as a self-reported history of congestive heart failure, coronary artery disease, or stroke. eGFR was calculated from serum creatinine using the CKD-EPI formula (Chronic Kidney Disease Epidemiology Collaboration), 15 and estimated ASCVD risk was calculated using the 2013 ACC/AHA ASCVD pooled cohort equation. 16 In SPRINT and ACCORD-BP, we used the CKD-EPI formula to estimate the glomerular filtration rate and estimated the ASCVD risk with the 2013 ACC/AHA pooled cohort equation. In ACCORD-BP, all included patients had a history of type 2 diabetes mellitus and a baseline glycohemoglobin of ≥7.5%.
Statistical Methods
In NHANES, analyses incorporated sampling weights to account for nonresponse bias and the sampling design. We used a bootstrap approach with 500 replicates to account for the variability in the estimate of the probability of persistent hypertension. 9 We estimated the prevalence of hypertension as the prevalence of hypertension in the bootstrap sample multiplied by the bootstrap probability of persistence; the final estimate and 95% confidence interval (CI) were the mean and 2.5/97.5th percentiles across bootstrap replicates, respectively (in the online-only Data Supplement).
Incident CVD rates were calculated separately in SPRINT and ACCORD-BP as the number of events in the primary composite end point divided by the total time at risk stratifying by BP value and prior use of BP medication. CIs were derived with a bootstrap approach using 500 replicates.
Analysis was performed using STATA version 11.0 (StataCorp) and R version 3.4.0 (R Foundation for Statistical Computing).
Results
Prevalence of Hypertension
The estimated prevalence of hypertension among US adults was 44.0% (95% CI, 42.2%-45.7%) using newly recommended BP thresholds as compared with 34.2% (95% CI, 32.5%-35.8%) using traditional thresholds. This represents an estimated absolute increase in hypertension prevalence of 9.8% (95% CI, 8.7%-11.1%) and a relative increase of 28.6% (95% CI, 25%-33.1%; Table 1 ).
The absolute increase in hypertension prevalence was largest for adults 40 to 59 years of age, men, those who were obese (Quetelet index ≥30 kg/m 2 ) or free of significant comorbidities, such as diabetes mellitus or CVD, and in those with eGFR ≥60 mL/min per 1.73 m 2 (Table 1 ; Figure) .
Characteristics of Individuals Classified as Hypertensive Under Newly Recommended BP Thresholds
Compared with US adults classified as hypertensive using traditional BP thresholds (≥140/90 mm Hg), participants reclassified as hypertensive (BP ≥130/80 and <140/90 mm Hg) were younger; less likely to have diabetes mellitus, CVD, or an eGFR <60 mL/min per 1.73 m 2 ; and had a lower estimated 10-year risk of ASCVD (Table 2) . Cell contents are proportions (%; 95% CI). All prevalence estimates account for the persistence of hypertension (in the online-only Data Supplement). ACR indicates albumin to creatinine ratio; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; and NHANES, National Health and Nutrition Examination Survey.
*Defined as SBP ≥140 mm Hg, DBP ≥90 mm Hg, and current use of antihypertensive medication. †Defined as SBP ≥130 mm Hg, DBP ≥80 mm Hg, and current use of antihypertensive medication.
Compared with SPRINT and ACCORD-BP, individuals who would be reclassified as having hypertension and be recommended for initiation of BP therapy based on 10-year ASCVD risk >10% were younger and more likely to be men; less likely to have a history of CVD, or an eGFR <60 mL/ min per m 2 ; and had a lower estimated 10-year ASCVD risk (Table 3) .
End Points in SPRINT and ACCORD-BP
The cumulative incidence of the primary composite cardiovascular end point in SPRINT and ACCORD-BP were 6% and 9% during a median follow-up time of 3.2 and 4.7 years, respectively. Of participants not on BP medications at baseline and with an SBP ≥130 or DBP ≥80 mm Hg and an SBP <140 and DBP<90 mm Hg, there were 10 events (2% of total) and 14 events (3% of total), in SPRINT and ACCORD-BP, respectively.
In each trial, incident rates of the primary end point in participants not on antihypertensive medications at baseline were substantially lower than the rates observed for participants on baseline BP medications (Table 4) .
Discussion
Implementation of the new ACC/AHA guidelines for hypertension diagnosis would lead to an estimated prevalence of hypertension of 44% among US adults, representing an absolute increase of ≈10%. Newly reclassified hypertensive individuals would be younger and have a lower prevalence of major comorbid conditions compared with adults traditionally diagnosed with hypertension. Furthermore, individuals who would be recommended to start BP therapy have a substantial lower CVD risk profile than most participants enrolled in the SPRINT and ACCORD-BP trials. In each of these trials, participants who were not on antihypertensive medications at baseline had a substantially lower CVD risk than participant on baseline antihypertensive medications.
We estimate that applying the newly recommended BP thresholds to hypertension diagnosis would reclassify an estimated 24 million adults with SBP 130 to 139 mm Hg or DBP 80 to 89 mm Hg who are not currently treated for hypertension and, based on a 10-year ASCVD risk of ≥10%, would recommend starting BP therapy on ≈4.5 million American adults. These estimates are lower than prior reports that have estimated the population impact of adopting the ACC/AHA guidelines in US adults. Muntner et al 6 estimated that 31 million American adults would be reclassified as having hypertension. The reason for the discrepancy is that in our analyses, Cell contents are N, mean (95% CI), or proportion (%; 95% CI). ASCVD indicates atherosclerotic cardiovascular disease; BMI, body mass index; BP, blood pressure; CI, confidence interval; DBP, diastolic BP; eGFR, estimated glomerular filtration rate; NHANES, National Health and Nutrition Examination Survey; and SBP, systolic BP.
*No hypertension was defined as SBP <130 mm Hg, DBP <80 mm Hg, and no treatment with antihypertensive medication. †Newly classified with hypertension was defined as SBP ≥130 or DBP ≥80 mm Hg and, SBP <140 mm Hg and DBP <90 mm Hg, and no treatment with antihypertensive medication. ‡Hypertension based on traditional criteria was defined as SBP ≥140 mm Hg, DBP ≥90 mm Hg, or current use of an antihypertensive medication. §In this group, 39% were classified as hypertensive based on SBP only, 43% based on DBP only, and 18% based on SBP and DBP. ‖In this group, 13% were classified as hypertensive based on SBP only, 2% on DBP only, 4% based on SBP and DBP, and 80% based on use of antihypertensive medications.
we account for the probability of the persistence of hypertension on our prevalence estimates, an approach recommended by most BP guidelines.
The new guidelines recommend treating hypertension to a target BP of <130/80 mm Hg based largely on results of the SPRINT trial, which demonstrated that targeting SBP <120 mm Hg reduced CVD events among participants at high CVD risk. 5 However, treatment targets are distinct from, and need not be identical to, thresholds used for diagnosis which we evaluate in this study. For example, hemoglobin A1c ≥6.5% is used to diagnose diabetes mellitus, whereas hemoglobin A1c <7% is a common treatment target.
14 This consideration is critical to interpret the results of SPRINT and ACCORD-BP, which were designed to evaluate the effectiveness of intensive treatment targets (but not of different diagnostic thresholds) in participants who were for the most part on baseline antihypertensive medications.
American adults who would be newly recommended to start antihypertensive medications have a lower CVD risk than participants in SPRINT and ACCORD-BP. This is supported by our findings of lower CVD risk-factor profile in NHANES participants compared with those in SPRINT and ACCORD-BP. Furthermore, CVD event rates in participants in these trials that were not on baseline antihypertensive medications, and, thus, that would most closely resemble the population recommended to start antihypertensive medications, Cell contents are N, mean (95% CI), or proportion (%; 95% CI). ACCORD indicates Action to Control Cardiovascular Risk in Diabetes; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; BP, blood pressure; CI, confidence interval; DSP, diastolic BP; eGFR, estimated glomerular filtration rate; NA, not applicable; NHANES, National Health and Nutrition Examination Survey; SBP, systolic BP; and SPRINT, Systolic Blood Pressure Intervention Trial.
were markedly lower than those of participants on baseline antihypertensive medications. These observations are important because prior research has shown a net benefit to risk balance of intensive BP reduction that is dependent on CVD risk, with individuals at highest CVD risk deriving most benefit. 7, 17 There is insufficient evidence to support the recommendation of starting antihypertensive medications in the newly reclassified population. As we show, only a minority of CVD events in SPRINT and ACCORD-BP occurred among participants in the lower BP threshold category who were not on baseline antihypertensive medications. In the HOPE-3 trial (Heart Outcomes Prevention and Evaluation) of adults with intermediate CVD risk and no history of CVD, participants with baseline BP <140/90 mm Hg had no significant benefit from treatment with candesartan plus hydrochlorothiazide, compared with placebo, on a composite primary CVD end point. 18 As opposed to SPRINT and ACCORD-BP, only 22% of HOPE-3 participants were taking BP medications. Although data from HOPE-3 may apply more closely to the population that would be recommended to start BP therapy compared with SPRINT and ACCORD-BP, no prior clinical trial has primarily evaluated the effect of BP therapy in this population.
Our study is limited in that NHANES 2013 to 2014 did not have repeated BP measurements to accurately classify persistent hypertension at the individual level. It is possible that our estimates of persistence may be imprecise because of secular trends in BP treatment and control. In addition, NHANES relied on self-report of CVD which may underestimate the prevalence of CVD. Moreover, the cross-sectional study design in NHANES precludes assessing associations of hypertension diagnoses with CVD events. Finally, owing to the small number of events in SPRINT and ACCORD-BP, we were unable to provide reliable estimates for the effect of intensive BP therapy in the newly reclassified population recommended for BP therapy.
In conclusion, the newly recommended thresholds for BP diagnosis would lead to a substantial increase in the prevalence of hypertension with the largest increase among adults at a low cardiovascular risk. Individuals who would be recommended to start BP therapy were not well represented and had a markedly lower CVD risk profile than participants in SPRINT and ACCORD-BP.
Perspectives
There is insufficient evidence to recommend initiation of BP therapy among US adults newly labeled as hypertensives using the ACC/AHA recommended thresholds. Future research should establish if lowering diagnostic thresholds for hypertension is associated with a reduction in cardiovascular disease burden. Composite primary outcome for ACCORD is nonfatal MI, nonfatal stroke, or CVD death; composite primary outcome for SPRINT is MI, HF, stroke, angina, or CVD death. ACCORD indicates Action to Control Cardiovascular Risk in Diabetes; BP, blood pressure; CI, confidence interval; CVD, cardiovascular disease; DBP, diastolic BP; HF, heart failure; IR, incident rate; MI, myocardial infarction; SBP, systolic BP; and SPRINT, Systolic Blood Pressure Intervention Trial.
*An additional 113 events occurred in 1749 participants with an SBP <130 and a DBP <80 mm Hg at randomization. Only 74 participants in this category were not on medications at baseline.
